Follistatins in glucose regulation in healthy and obese individuals
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: It has been suggested recently that follistatin (FST) and its homologous protein, follistatin‐like 3 (FSTL3), may be a therapeutic target in the treatment of type 2 diabetes because of their glucose‐regulatory effects in rodents. Materials and Methods: We investigated this hypothesis in humans by studying the physiology of a possible glycaemia–follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity. Results: In healthy individuals, circulating FST decreases after intravenous or oral glucose intake compared to controls, indicating the presence of a negative feedback mechanism. In morbid obesity, insulin resistance, glycaemia, circulating FST and FSTL3 are all reduced (by 22%‐33%) after Roux‐en‐Y gastric bypass (RYGB) and sleeve gastrectomy. Importantly, the changes in circulating FST 3 months after bariatric surgery are associated prospectively with the changes in glucose, insulin, HOMA‐IR and HbA1c observed 6 months postoperatively in individuals with and without type 2 diabetes. Conclusions: Our findings provide evidence of an important role of FST in glucose homeostasis in healthy individuals as well as in severely obese individuals with insulin resistance and type 2 diabetes. Our data extend recent results from animal studies to humans and support the need for further evaluation of FST inactivation strategies for targeting hyperglycaemia and insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 1×
“Specifically, it binds to activin A and activin B, thus suppressing the stimulatory effects of these hormones on the hypothalamic–pituitarygonadal axis, and it also binds to myostatin, inactivating its inhibitory effects on muscle growth and differentiation.(7,21) Both activins, as well as myostatin, mediate their eff…”
BackgroundCirculating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125 · cited 7×
“These findings suggest that a negative feedback loop of glucose, but not of free fatty acids, affects FST.”
BackgroundInfluentialHansen, J. S., Pedersen, B. K., Xu, G., Lehmann, R., Weigert, C., & Plomgaard, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1681 · Cited by 106
Inactivating hepatic follistatin alleviates hyperglycemia
Tao, R., Wang, C., Stöhr, O., Qiu, W., Hu, Y., Miao, J., Dong, X. C., Leng, S., Stefater, M., Stylopoulos, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0048-0 · Cited by 104 · cited 10×
“In conclusion, our findings provide evidence in humans of an important role of FST in glucose homeostasis in healthy individuals as well as in individuals with severe obesity, insulin resistance and T2D.”
BackgroundInfluentialMurton, A. J., Marimuthu, K., Mallinson, J. E., Selby, A. L., Smith, K., Rennie, M. J., & Greenhaff, P. L. (2015) · Diabetes · doi:10.2337/db15-0021 · Cited by 97 · cited 1×
“Current efforts in on-going clinical trials are focusing on the evaluation of actRII-blockers for the treatment of obesity, insulin resistance and diabetes,(22) aiming to improve glucose homeostasis by promoting muscle growth, despite the absence of a profound musclemass deficit in these conditions.(23) Our findings,…”
Kokkinos, A., Alexiadou, K., Liaskos, C., Argyrakopoulou, G., Balla, I., Tentolouris, N., Moyssakis, I., Katsilambros, N., Vafiadis, I., Alexandrou, A., et al. (2013) · Obesity Surgery · doi:10.1007/s11695-012-0743-8 · Cited by 90
Self-citationBimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88
Hansen, J., Rinnov, A., Krogh‐Madsen, R., Fischer, C. P., Andreasen, A. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Plomgaard, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2415 · Cited by 71
Circulating follistatin in relation to energy metabolism
Hansen, J. S., & Plomgaard, P. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.06.002 · Cited by 62
Perakakis, N., Mougios, V., Fatouros, I., Siopi, A., Draganidis, D., Peradze, N., Ghaly, W., & Mantzoros, C. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01056 · Cited by 52
Self-citation
Research works printed but not linked: 12
- 10.1210/jc.2011-1453 · DOI
- 10.1016/j.metabol.2018.05.003 · DOI · Paper page
- 10.1210/jc.2011-1665 · DOI · Paper page
- 10.1016/j.metabol.2016.07.009 · DOI · Paper page
- 10.1210/er.2014-1003 · DOI · Paper page
- 10.1016/j.metabol.2014.10.007 · DOI
- 10.1073/pnas.0607966104 · DOI · Paper page
- 10.1590/1414-431X20143869 · DOI
- 10.1210/en.2012-1844 · DOI
- 10.1210/jc.2015-4141 · DOI
- 10.1001/jamasurg.2014.2440 · DOI · Paper page
- 10.1016/j.soard.2018.03.003 · DOI · Paper page
Cited by
The Liver as an Endocrine Organ—Linking NAFLD and Insulin Resistance
Watt, M. J., Miotto, P. M., De Nardo, W., & Montgomery, M. K. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00034 · Cited by 615
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Self-citationPerakakis, N., Polyzos, S. A., Yazdani, A., Sala-Vila, A., Kountouras, J., Anastasilakis, A. D., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154005 · Cited by 137
Self-citationPerakakis, N., Kokkinos, A., Peradze, N., Tentolouris, N., Ghaly, W., Pilitsi, E., Upadhyay, J., Alexandrou, A., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153997 · Cited by 93
Self-citationRelative Energy Deficiency in Sport (REDs): Endocrine Manifestations, Pathophysiology and Treatments
Angelidi, A. M., Stefanakis, K., Chou, S. H., Valenzuela-Vallejo, L., Dipla, K., Boutari, C., Ntoskas, K., Tokmakidis, P., Kokkinos, A., Goulis, D. G., et al. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae011 · Cited by 83
Self-citation
Metadata
- Authors
- Perakakis, N., Kokkinos, A., Peradze, N., Tentolouris, N., Ghaly, W., Tsilingiris, D., Alexandrou, A., & Mantzoros, C. S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-12-03
- Volume
- 21
- Issue
- 3
- Pages
- 683-690
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2900161728
- Cited by
- 56
- References
- 11
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Deutsche Forschungsgemeinschaft (389891681, 389891681 (PE 2431/2‐1))
- National Institutes of Health (K24DK081913)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.